A drug-delivering medical device for treating a medical condition associated with a body lumen, the body lumen comprising a plurality of layers, the drug-delivering insertable medical device comprising: a balloon catheter; and an inflatable balloon positioned on the balloon catheter, the inflatable balloon having a hydrophilic surface, at least one portion of the hydrophilic surface being coated with a plurality of nano-carriers, a nano-carrier of the plurality of nano-carriers comprising a drug surrounded by an encapsulating medium, wherein a surface of the nano-carrier is devoid of the drug and wherein the encapsulating medium comprises a phospholipid, wherein the plurality of nano-carriers have a single average diameter, wherein the single average diameter ranges between 10 nm to 1000 nm, wherein the plurality of nano-carriers comprises a first set of nano-carriers having a first average diameter suitable for penetrating a first layer of the plurality of layers of the body lumen ranging from 800 nm to 1000 nm, a second set of nano-carriers having a second average diameter suitable for penetrating the first layer and a second layer of the plurality of the body lumen ranging from 300 nm to 800 nm, and a third set of nano-carriers having a third average diameter suitable for penetrating the first layer, the second layer and a third layer of the plurality of the body lumen ranging from 10 nm to 300 nm, wherein the drug is selected from a group consisting of sirolimus, paclitaxel, tacrolimus, clobetasol, dexamethasone, genistein, heparin, beta-estadiol, rapamycin, everolimus, ethylrapamycin, zotarolimus, ABT-578, Biolimus A9, docetaxel, methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride, mitomycin, sodium heparin, low molecular weight heparin, heparinoid, hirudin, argatroban, forskolin, vapiprost, prostacyclin, dextran, D- phe-pro-arg-chloromethylketone, dipyridamole, glycoprotein Ilb/DIa, recombinant hirudin, bivalirudin, nifedipine, colchicines, lovastatin, nitroprusside, suramin, serotonin blockers, a steroid, thioprotease inhibitors, triazolopyrimidine, nitric oxide,nitric oxide donors, super oxide dismutase, super oxide dismutase mimetics, estradiol, aspirin, angiopeptin, captopril, cilazapril, lisinopril, permirolast potassium, alpha-interferon, and bioactive RGD, at least one flavonoid, estrogen, antibodies, genetically engineered epithelial cells, wherein the at least one flavonoid is selected from a group comprising at least one of narigenin, naringin, eriodictyol, hesperetin, hesperidin (esperidine), kampferol, quercetin, rutin, cyanidol, meciadonol, catechin, epi-gallocatechin- gallate, taxifolin (dihydroquercetin), genistein, genistin, daidzein, biochanin, glycitein, chrysin, diosmin, luetolin, apigenin, tangeritin and nobiletin. a balloon catheter; and an inflatable balloon positioned on the balloon catheter, the inflatable balloon having a hydrophilic surface, at least one portion of the hydrophilic surface being coated with a plurality of nano-carriers, a nano-carrier of the plurality of nano-carriers comprising a drug surrounded by an encapsulating medium, wherein a surface of the nano-carrier is devoid of the drug and wherein the encapsulating medium comprises a phospholipid, wherein the plurality of nano-carriers have a single average diameter, wherein the single average diameter ranges between 10 nm to 1000 nm, wherein the plurality of nano-carriers comprises a first set of nano-carriers having a first average diameter suitable for penetrating a first layer of the plurality of layers of the body lumen ranging from 800 nm to 1000 nm, a second set of nano-carriers having a second average diameter suitable for penetrating the first layer and a second layer of the plurality of the body lumen ranging from 300 nm to 800 nm, and a third set of nano-carriers having a third average diameter suitable for penetrating the first layer, the second layer and a third layer of the plurality of the body lumen ranging from 10 nm to 300 nm, wherein the drug is selected from a group consisting of sirolimus, paclitaxel, tacrolimus, clobetasol, dexamethasone, genistein, heparin, beta-estadiol, rapamycin, everolimus, ethylrapamycin, zotarolimus, ABT-578, Biolimus A9, docetaxel, methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride, mitomycin, sodium heparin, low molecular weight heparin, heparinoid, hirudin, argatroban, forskolin, vapiprost, prostacyclin, dextran, D- phe-pro-arg-chloromethylketone, dipyridamole, glycoprotein Ilb/DIa, recombinant hirudin, bivalirudin, nifedipine, colchicines, lovastatin, nitroprusside, suramin, serotonin blockers, a steroid, thioprotease inhibitors, triazolopyrimidine, nitric oxide,nitric oxide donors, super oxide dismutase, super oxide dismutase mimetics, estradiol, aspirin, angiopeptin, captopril, cilazapril, lisinopril, permirolast potassium, alpha-interferon, and bioactive RGD, at least one flavonoid, estrogen, antibodies, genetically engineered epithelial cells, wherein the at least one flavonoid is selected from a group comprising at least one of narigenin, naringin, eriodictyol, hesperetin, hesperidin (esperidine), kampferol, quercetin, rutin, cyanidol, meciadonol, catechin, epi-gallocatechin- gallate, taxifolin (dihydroquercetin), genistein, genistin, daidzein, biochanin, glycitein, chrysin, diosmin, luetolin, apigenin, tangeritin and nobiletin.